Immucell Profit Margin

Immucell (ICCC) currently reports a profit margin of 2.57% as of June 2026. That compares with 5.3% in the prior-year period — down 51.5% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Immucell's profit margin history and peer comparisons.

Immucell's profit margin decreased from 5.3% to 2.57% — a 51.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Immucell's profit margin of 2.57% is lower than the Healthcare sector average of 21.34%. That is roughly 88.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Immucell's current 2.57% should be judged against Healthcare norms (sector average: 21.34%) and against ICCC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 2.57%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Immucell, and consider following ICCC for alerts when major investors trade the stock.